China Securities News, Shanghai Stock Exchange: After the United States, Zhifei Biology has once again obtained a European patent certificate. The company announced on November 27 evening that its wholly-owned subsidiary, Beijing Zhifei Lvyu Biological Pharmaceutical Co., Ltd., recently received an invention patent certificate issued by the European Patent Office. The patent name is COMBINATION VACCINE AGAINST RESPIRATORY SYNCYTIAL VIRUS INFECTIONS AND IMMUNE RESPONSE INDUCTION METHOD THEREOF, which is a combination vaccine against respiratory syncytial virus infections and a method for inducing immune response. The patent number is EP4032548, and the estimated expiration date of the patent right is August 11, 2041.

It is learned that this invention patent was obtained by Zhifei Lvyu in collaboration with Beijing Jiaotong University during the development of a respiratory syncytial virus (RSV) vaccine. The RSV vaccine developed through this collaborative development has already obtained patent authorization in China, Russia, and the United States.

ZhiFei Biologics stated that the company has overcome the technical barriers of the international market and obtained a patent certificate in Europe for the first time, laying the foundation for its global expansion. This is beneficial for the company to further improve its intellectual property protection system, leverage its own intellectual property advantages, promote technological innovation, advance its international development strategy, and enhance its core competitiveness.

https://finance.eastmoney.com/a/202511273576866070.html